InsidersTradesSigma
메타바이오메드 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 메타바이오메드 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has published 35 reports. Market capitalisation: €103.1bn. The latest transaction was disclosed on 12 June 2026 (Other). Among the most active insiders: 오지수. All data is free.
35
Insider Decl.
0
Thresholds
€1,687
15 ops.
Buy Volume
·
0 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 5,516 of 25,514 companies
66.1
score / 100
Value68
Quality64
FCF yld-0.6%
Earn yld11%
EV/EBITDA6.8x
ROE·
Gross mgn52%
Net mgn11%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 June 2026
Declarations35 total
25 of 35 declarations